Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | HTR1D | P28221 | 1/20 | 0.53 |
| ▸ | HTR1B | P28222 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | BTK | Q06187 | 1/20 | 0.49 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11623785 | 0.81 | BTK (0.54) | MEN1KMT2AHTTBTKPOLB | |
| SCHEMBL16585940 | 0.78 | NPC1 (0.49) | SMN1; SMN2NPC1RAB9AKMT2APOLB | |
| SCHEMBL1482081 | 0.77 | HDAC3 (0.56) | SMN1; SMN2MEN1KMT2AHTTPOLB | |
| SCHEMBL890092 | 0.77 | SMN1; SMN2 (0.51) | SMN1; SMN2MEN1KMT2APOLBHDAC3 | |
| SCHEMBL3411277 | 0.76 | MDM4 (0.54) | SMN1; SMN2RAB9AMEN1KMT2ABTK | |
| SCHEMBL4196369 | 0.74 | ALDH1A1 (0.52) | SMN1; SMN2NPC1HTTPOLBTSHR | |
| SCHEMBL13469106 | 0.74 | MC4R (0.58) | HTR1ASMN1; SMN2KMT2APOLBHDAC3 | |
| SCHEMBL754058 | 0.74 | SMN1; SMN2 (0.54) | SMN1; SMN2MEN1KMT2ASUCNR1POLB | |
| SCHEMBL13159555 | 0.74 | MAPK1 (0.64) | SMN1; SMN2NPC1MEN1KMT2AHTT | |
| SCHEMBL3454127 | 0.74 | HDAC3 (0.56) | SMN1; SMN2KMT2AHTTPOLBHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678157-A4 | HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | REDDY US THERAPEUTICS INC (US) | 2009-03-18 | — | — | EP | disclosed |
| EP-1436291-B1 | INDOLIZINES AS KINASE PROTEIN INHIBITORS | AVENTIS PHARMA SA (FR) | 2009-01-14 | — | — | EP | disclosed |
| CN-100391958-C | Compound (I) | AVENTIS PHARMA SA (FR) | 2008-06-04 | — | — | CN | disclosed |
| US-20070238734-A1 | JNK INHIBITORS | SANOLI-AVENTIS (FR) | 2007-10-11 | — | — | US | disclosed |
| US-7148215-B2 | Prodrugs as antihistamines or anticarcinogenic agents | AVENTIS PHARMA S.A. (FR) | 2006-12-12 | — | — | US | disclosed |
| EP-1678157-A2 | HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | Reddy US Therapeutics, Inc. (US) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042712-A2 | HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THEREOF | REDDY US THERAPEUTICS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005040163-A1 | HETEROCYCLIC COMPOUNDS THAT BLOCK THE EFFECTS OF ADVANCED GLYCATION END PRODUCTS (AGE) | DR. REDDY'S LABORATORIES LTD (IN) | 2005-05-06 | — | — | WO | disclosed |
| US-20050009831-A1 | Pyrrolo[1,2-a]pyrazine-8-carboxamides are JNK inhibitors, useful as anticarcinogenic agents | AVENTIS PHARMA S.A, (FR) | 2005-01-13 | — | — | US | disclosed |
| CN-1556807-A | Chemical compounds | �㶫��������ҽҩ�ɷ�����˾ | 2004-12-22 | — | — | CN | disclosed |
| EP-1436291-A2 | INDOLIZINES AS KINASE PROTEIN INHIBITORS | Aventis Pharma S.A. (FR) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003024967-A2 | INDOLIZINES AS KINASE PROTEIN INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238734-A1 | JNK INHIBITORS | MAP3K7, MAPKAPK2, MAPK7 | HTR1A 3462/4885HTR1D 3609/4885HTR1B 3175/4885 |
| US-20050009831-A1 | Pyrrolo[1,2-a]pyrazine-8-carboxamides are JNK inhibitors, useful as anticarcinogenic agents | CNKSR1, ROS1, NRAS | HTR1A 2041/4885HTR1D 1442/4885HTR1B 2806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.